AI assistant
EKF DIAGNOSTICS HOLDINGS PLC Major Shareholding Notification 2020
7617_mrq_2020-11-26_d95082ce-63b1-4482-8b79-18d21c4746e7.html
Major Shareholding Notification
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 5458G
EKF Diagnostics Holdings PLC
26 November 2020
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Sale of shares in Renalytix AI plc
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has sold 1,675,000 ordinary shares in Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) at a price of £4.60 per ordinary share, in response to strong institutional demand. The sale has resulted in gross proceeds of £7.705m to EKF and generated a profit of over £5.6m after dealing expenses.
Following this transaction EKF will continue to hold 1,002,981 ordinary shares in Renalytix AI plc.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
| Christopher Mills, Non-executive Chairman | Tel: +44 (0) 29 2071 0570 | |
| Julian Baines, CEO | ||
| Richard Evans, FD & COO | ||
| N+1 Singer | Tel: 020 7496 3000 | |
| Aubrey Powell / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking) |
||
| Walbrook PR Limited | Tel: +44 (0) 20 7933 8780 or [email protected] | |
| Paul McManus / Lianne Cawthorne | Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 | |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFELLLBFLLFBD